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Abstract
Purpose Human DNA topoisomerases I and II (topo-I
and -II) are essential for vital cellular processes such as
DNA replication, transcription, translation, recombination,
and repair. In the present study, we correlate topo-I and -II
expression and outcome after chemotherapy in primary and
relapsed colorectal cancer.
Patients and methods Patients with colorectal cancer that
had recurred, following surgery and adjuvant chemotherapy
and underwent a second operation were included in the
present study. All had undergone surgical resection of the
primary tumor and received post-operatively 5-FU-based
(5FU + Leucovorin, Mayo Clinic regimen) adjuvant che-
motherapy. Tumor tissue was collected at the initial opera-
tion from the primary tumor and at the time of recurrence
(during the second operation following chemotherapy). All
tissue samples were analyzed for levels of expression of
both topo-I and topo-IIa using standard three-step immuno-
histochemistry on paraYn sections.
Results Forty patients were included. Levels of expres-
sion of topo-I and topo-II were higher in malignant cells
from tumor recurrences compared to primary tumors
(P = 0.0001 for both). There was a statistically signiWcant
positive relationship between patients age and levels of
topo-I (P = 0.011) and topo-II (P = 0.011) expression.
Conclusions The study results reported here underscore
the role of topoisomerase expression in colorectal cancer
and suggest a potential role in tumor recurrence.
Keywords Topoisomerase I · Topoisomerase II · 
Colorectal cancer · 5-FU · Chemotherapy
Introduction
The aim of the present study was to investigate whether
chemotherapy with 5-FU alters the levels of topoisomerase
I (topo-I) and II (topo-II) in neoplastic tissues from patients
with colorectal cancer. To this end, we examined the rela-
tionship between clinical data and the expression of topo I
and II in patients treated with 5-FU post-operatively and
who underwent surgery at recurrence.
Human DNA topo-I is an essential nuclear enzyme for
vital cellular processes such as DNA replication, transcrip-
tion, translation, recombination and repair. Topo-I unwinds
and uncoils the supercoiled DNA double helix by transiently
cleaving one of the two strands and allowing its rotation
over the other, following which topo-I reseals the cleaved
strand [1–5]. Topo-II works in a similar manner, with the
diVerence that it cleaves both DNA strands, allowing the
passage of an intact double helix through the break. The
entire reaction takes place at the expense of ATP hydrolysis
[6]. In contrast to topo-I, which is monomeric, two homolo-
gous but distinct isoforms of type II human topoisomerases
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have been identiWed, DNA topo-II and II [6, 7]. The  iso-
form is the type II topoisomerase that was originally
described and characterized in mammalian species [6].
Several studies have shown topo-II to be a reliable
marker of cell proliferation in tumors [8, 9]. In contrast to
topo-II, topo-I levels are not cycle-speciWc and remain sta-
ble throughout the cell cycle [10]. Topo-II plays important
roles in DNA synthesis and transcription, as well as chro-
mosomal segregation during mitosis. Beyond its physiolog-
ical functions, topo-II is reported to be a sensitive and
speciWc marker of actively proliferating cells (in the late S,
G2 and M-phases of the cell cycle) and has been used as a
proliferation marker in studies of colorectal cancer [7, 8,
10]. In addition to the well described role of the three
MDR-related proteins, topo-II has been implicated in drug
resistance of tumor cells [9].
Topo-I catalytic activity has been evaluated in various
studies and has been detected in all normal tissues at fairly
constant levels [10]. Additional parameters were further
investigated: topo-I immunoreactive protein levels were
estimated by Western blot analysis, and topo-I gene expres-
sion (topo-I mRNA) was evaluated by Northern blot analy-
sis. With regard to colorectal tumors, they were found to
exhibit 5- to 35-fold increases in topo-I levels compared to
the adjacent normal colonic mucosa [11].
Topo-I expression has also been evaluated by immuno-
histochemistry in paraYn-embedded human tissues [12],
and its expression has been demonstrated in numerous neo-
plastic tissues. Increased topo-I has been shown in ovarian
carcinomas (elevated topo-I expression in 43% of tumors)
[12]; colorectal carcinomas (ranging from 43–86% in vari-
ous studies) [13–15]; testicular tumors (30–38% in semino-
mas, 30% in embryonal carcinomas, and 100% in teratomas
and yolk sac tumors) [16]; transitional carcinoma of the
bladder (overexpression in 77%) [17], and renal cell carci-
nomas (ranging from 36–100% according to grade) [18];
malignant melanomas (overexpression in 41.6%) [19]; gas-
tric carcinomas (overexpression in 68%) [20]; sarcomas
(high levels of topo-I in 13%) [21]; breast carcinomas (over-
expression in 41%) [22], oral dysplasias, and squamous cell
carcinomas (overexpression in 79 and 92%, respectively)
[23, 24]. In normal tissues, topo-I expression appeared to be
higher in the germinal centers of the tonsil and in the muco-
sal lymphocytes of the colon, while topo I positivity was
also detected in the glandular epithelium of the colon [12].
Patients and methods
Patients
Forty patients with colorectal cancer that had recurred fol-
lowing surgery and adjuvant chemotherapy who underwent
a second operation were included in this study. All had
undergone surgical resection for their primary tumor and
received post-operatively 5-FU-based [5FU and Leucovo-
rin (LV), Mayo Clinic regimen] adjuvant chemotherapy
[25]. Patients characteristics are described in Table 1.
Study plan
Tumor tissue was collected during the initial operation
from the primary tumor, before the administration of any
adjuvant chemotherapy and also at the time of recurrence
(during the second operation following chemotherapy). All
these tissues were analyzed for expression of both topo-I
and topo-II.
Determination of topo-I and topo-II
The expression of topo-I and topo-II was studied on par-
aYn sections by a standard three-step immunohistochemis-
try. Topogen, an anti-topo-I monoclonal antibody (mAb)
(2012-3) was applied. Topogen is a mouse mAb (IgG2b
isotype); its epitope has not been mapped [26–28]. The pri-
mary mAb JH2.7 for topo-II (Biocare Medical, CA, USA)
is a mouse mAb (IgG1 isotype) that recognizes a 170-kDa
protein, the epitope of which maps between aminoacid
854–1447 of topo-II [27–29]. Counterstaining with hema-
toxylin was applied in the end of the classical immunohis-
tochemistry procedure.
Table 1 Patients characteristics
Patients (n)4 0
Gender
Men 25
Women 15
Median age at diagnosis (years) 58 (35–75)
Performance status (WHO), 0–1 40
Location of primary tumor
Right colon 6
Left colon 28
Rectum 6
Stage (Dukes’)
B2 13
C2 7
Relapse
Local 17
Distant 23
DiVerentiation
Well 2
Moderate 31
Poor 7
Disease-free survival (months) 18 (range, 6–79)Cancer Chemother Pharmacol (2009) 64:391–398 393
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Positive and negative controls
For the expression of topo-I and –IIa, normal human tonsil
tissues immunostaining served as positive controls. Non-
speciWc, isotype-matched monoclonal Abs worked well as
substitute negative controls [26–29].
Determination of topo-I and topo-II expression
First step Sections were examined for quantiWed immuno-
reactivity by two independent investigators blinded to any
relevant patient clinical data. They evaluated more than
1,000 neoplastic cells in consecutive areas of neoplastic tis-
sue. The numbers of positive cells were then expressed as a
percentage of labeled tumor cells with respect to the total
number of tumor cells that were evaluated. Immunostaining
for topo-I and -II was graded according to the percentage
of tumor cells staining positive (and § for <5%, + for 5–
50% and ++ for 50 to 75% of cells with positive staining)
and intensity of staining (weakly positive, moderately posi-
tive, or strongly positive). To simplify the scoring, we
graded them as 0 (negative cells), 1 (§ and/or <5%), 2 (+
and/or 5–50%), 3 (++ and/or 50–75%). Then, the sections
were evaluated classiWed in pairs (one section from the Wrst
surgery and one section from the second surgery for each
patient).
Second step The percentages of immunoreactive malig-
nant cells were calculated using an image analysis system
with an appropriate software package [Sigma Scan Pro,
Version 5.0 (SPSS Science, Erkrath, Germany)]. The ratio
was calculated as a percentage of immunohistochemically
positive neoplastic cells over the total number (stained and
unstained) of neoplastic cells. The membrane, cytoplasmic
or nuclear intensity of the speciWc immunohistochemical
stain, was also assessed. All the positively stained cells
were classiWed in two groups (weakly stained and strongly
stained).
DNA ploidy of neoplastic cells was evaluated by image
DNA cytometry performed on Feulgen-stained sections.
Images were acquired using a Zeiss Axiolab microscope
(Carl Zeiss Jena GmbH, Jena, Germany) with a mechanical
stage, Wtted with a SONY-iris CCD video camera (SONY
Corporation, Tokyo, Japan). The latter was connected to a
Pentium II personal computer which included the relevant
software. Slides were examined at low power magniWcation
(40£) to identify the areas with the highest cellularity. In
each case, a total number of ¸200 Feulgen-stained nuclei
was selected at high power magniWcation (400£) and
stored as JPEG Wle [1,550 £ 1,070 pixels, 16.7 million col-
ors (24-bit)]. Then the images were converted to gray scale
and the staining intensity of the Feulgen-stained nuclei was
measured semi-automatically. A classiWcation of the nuclei
in pairs according to their staining intensity followed.
Finally, the graphic presentation of the nuclei demonstrat-
ing their distribution according to their DNA content was
also performed.
Statistical analysis
All analyses were performed with SPSS version 10.1
(Statistical Product and Service Solutions; SPSS Inc., Chicago,
IL, USA). We used McNemar’s paired Chi-square test to
assess the possible alteration of the levels of topoisome-
rases after chemotherapy with 5-FU. Fisher’s exact test was
performed in order to assess the possible relationship of
topoisomerase increase with gender, Dukes’ stage, tumor
grade and localization. Mann–Whitney U Test was per-
formed to assess a possible relationship between patient age
and alteration in topoisomerases levels.
Results
Patients
Forty patients were included in the present study. Of these,
25 were men and 15 were women. The median age was
58 years (range, 35–75). All patients had a performance sta-
tus (PS) of 0–1. Tumor localization at the time of diagnosis
was: right colon 6, left colon 28, and rectum 6. According
to pathological classiWcation, 13 patients had Dukes B2
tumors, and the remaining 27 Dukes C. With regard to
diVerentiation, 2 tumors were well diVerentiated, 31 moder-
ately and, 7 were poorly diVerentiated. Of all these patients,
17 relapsed locally and 23 with distant metastases, with a
median relapse-free interval of 18 (range, 6–79) months
(Table 1). All patients who entered the trial were evaluable
for analysis.
Ploidy
Out of 40 primary tumors, 12 were highly aneuploid and
the remaining 28 were moderately aneuploid. There was no
association between the degree of DNA aneuploidy and the
expression of any of the analyzed markers.
Topoisomerase I
Immunohistochemical analysis revealed that levels of topo-
I expression were higher in malignant cells from tumor
recurrences compared to cells from the primary tumors
(P = 0.0001) (Table 2; Fig. 1); decreased in grade 1
(P = 0.007) and increased in grade 3 (P = 0.003) (Table 2).
In image analysis evaluation, there was a signiWcant
increase in malignant cells from the tumor recurrences
(P = 0.0001) (Table 3); low expression was noticed in394 Cancer Chemother Pharmacol (2009) 64:391–398
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range 1–5 (P = 0.0001) and 26–30 (P = 0.0143) (Table 3;
Fig. 3). The increase in topo-I levels was not signiWcantly
correlated with gender, performance status (WHO), loca-
tion of the primary tumor, Dukes’ stage, grade of diVerenti-
ation, and localization of relapse. There was a statistically
signiWcant relationship between the age of patients and
the expression of topo-I (P = 0.011). Patients with an
increased expression of topo-I levels were older in age
(median = 62.5) than patients without increased expression
(median = 50).
Topoisomerase II
Malignant cells from tumor recurrences showed statisti-
cally signiWcantly increased levels of topo-II, compared to
those of the primary tumors (P = 0.0001) (Table 2; Fig. 2);
while topo-II levels were decreased in grade 3 lesions
(P = 0.0001) (Table 2; Fig. 4). In image analysis, there was
a signiWcant increase in malignant cells from tumor recur-
rences (P = 0.0001) (Table 3); low expression was noticed
in the range of 16–20 (P = 0.0143) (Table 3). There was a
statistically signiWcant relationship between the age of
patients and increased levels of expression of topo-II
(P = 0.011). Levels of topo-II expression were higher in
malignant cells from tumor recurrences compared to cells
from primary tumors (P = 0.0001). There was a statistically
signiWcant positive correlation between the age of patients
and increased levels of expression topo-II ( P =0 . 0 1 1 ) .
The increase in topo-II levels did not demonstrate any sig-
niWcant correlations with gender, age, PS (WHO), localiza-
tion of primary tumor, Dukes’ stage, tumor grade, and
location of relapse when compared to topo-II levels in the
primary tumors (P = 0.0001).
Discussion
In our study, 33 out of 40 (83%) samples of colorectal can-
cer stained positive for topoisomerase (Table 2; Fig. 3).
This Wnding is in close agreement with the results of Staley
et al. [14], who reported 86% of positive staining in 29
samples, but in contrast with the results from Boonsong
et al. [13], who demonstrated a lower percentage of cells
expressing topo-I; 51% of the samples, including 24.4%
with >50% positive tumor cells [13]. Topo-I immunoreac-
tivity was conWned to the nucleus in all samples, being con-
sistent with the role of topo-I as a nuclear protein. For topo-
II, 21 out of 40 (52%) samples of colorectal cancer stained
positive (Table 2; Fig. 4), including 10/40 (25%) with weak
positive staining (grade 1). This Wnding was conWrmed by
Image Analysis (Table 3). These data are consistent with
those reported by Burden and OsheroV [6].
In this study, we present signiWcantly increased topo-I
and topo-I expression in recurrent colorectal tumors,
reinforcing the view that their expression is likely part of
Fig. 1 Topoisomerase I (Topo-I) expression in relation to tumor grade
according to immunohistochemical evaluation
Table 2 Photomicroscopic 
evaluation
Examined parameters Photo, microscopic evaluation P
Grade First evaluation Second evaluation
Topoisomerase I 0 7 0 0.0117
1 13 1 0.0007
2 17 26 0.0722
3 3 13 0.0103
Increased: 25, decreased: 0, no change: 15, P =0 . 0 0 0 1
Topoisomerase IIa 0 0 0 1
1 10 2 0.0252
2 30 28 0.8027
3 0 10 0.0010
Increased: 18, decreased: 0, no change: 22, P =0 . 0 0 0 1Cancer Chemother Pharmacol (2009) 64:391–398 395
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the malignant cells phenotype in recurrent colorectal carci-
nomas. This observation is in agreement with previous
studies [15, 30], which demonstrated a direct correlation
between thymidylate synthase (TS) and topo-I tumor
expression and hypothesized, similar to TS [31], that high
topo-I expression is related to a more aggressive biological
phenotype. Of note, increased topo-II expression charac-
terizes rapidly proliferating cells [6] and represents an
accepted marker of aggressive tumor behavior [32].
Since the increase of topo-I and -II expression was
demonstrated following 5-FU-based treatment, it is tempt-
ing to attribute this change to 5-FU. High levels of topo-I
correlate with sensitivity to camptothecins (irinotecan and
topotecan) [17], whereas high levels of topo-II correlate
Table 3 Image analysis 
evaluation (%)
Range First 
sample (no.)
Second 
sample (no.)
P Range First 
sample (no.)
Second 
sample (no.)
P
Topoisomerase I
0 0 0 1 36–40 3 0 0.2405
1–5 21 1 0.0001 41–45 1 1 1.000
6–10 4 0 0.1156 46–50 1 1 1.000
11–15 2 4 0.6752 51–55 2 4 0.6752
16–20 3 5 0.7119 56–60 0 4 0.1156
21–25 2 3 1 61–65 0 5 0.0547
26–30 1 9 0.0143 66–70 0 0
31–35 0 3 0.2405 71–80 0 0
Topoisomerase IIa
0 0 0 1 36–40 2 3 1
1–5 10 4 0.1395 41–45 5 1 0.2007
6–10 6 5 1 46–50 0 3 0.2405
11–15 5 2 0.4315 51–55 0 2 0.4937
16–20 9 1 0.0143 56–60 0 0 1
21–25 0 5 0.0547 61–65 0 1 1
26–30 3 3 1 66–70 0 2 0.4937
31–35 0 3 0.2405 71–80 0 5 0.0547
Total First determination Second determination P
Mean Median Range Mean Median Range
Topoisomerase I 13.875 4.5 1–54 35.375 29.5 4–65 0.0001
Topoisomerase IIa 16.775 15 1–45 34.575 31 2–79 0.0001
Fig. 2 Topoisomerase II (Topo-II) expression in relation to tumor
grade according to immunohistochemical evaluation
Fig. 3 Dispersion diagram of topoisomerase I (Topo-) expression as
assessed by immunohistochemistry396 Cancer Chemother Pharmacol (2009) 64:391–398
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with sensitivity to etoposide, a known topo-II-targeting
agent [32]. Thus, it is reasonable to consider applying these
agents sequentially for the treatment of colorectal cancer;
i.e. 5-FU ! irinotecan and 5-FU ! etoposide.
Irinotecan (CPT-11), a water soluble camptothecin
derivative, is a speciWc potent inhibitor of topo-I [33]. In a
European phase II study, irinotecan achieved response rates
of 19% in chemotherapy-naive patients and 18% in pre-
treated patients with advanced disease [34].
Drugs that target topo-II, such as etoposide (VP-16),
doxorubicin, and mitoxantrone, are among the most eVec-
tive anticancer drugs in clinical use. Etoposide destroys
cells by inhibiting the ability of topo-II to ligate nucleic
acids cleaved during the double-stranded DNA passage
reaction [35].
Irinotecan yielded response rates of 15–25% in 5-FU-
refractory patients [36–44], not dissimilar to those observed
in Wrst-line treatment of colorectal cancer (18–32%) [45–
47] and in contrast to the expected decreasing response rate
from the application of irinotecan in second-line treatment.
Treating patients with irinotecan upon progression to 5-FU/
LV seems to be yielding more signiWcant results compared
to the opposite sequence, based in our previous experience,
where the best results with sequential monotherapies were
obtained when 5-FU/LV was followed by irinotecan (5-FU/
LV ! CPT11) at disease progression or relapse [41].
With regard to irinotecan eYcacy, in vitro data suggest
that topo-I expression could be regarded as an important
cellular sensitivity determinant [16]. In particular,
decreased DNA topo-I expression was correlated with cam-
ptothecin-resistant cell lines [27], while Jansen et al. [36]
reported a positive correlation between irinotecan sensitiv-
ity and topo-I activity.
Topo-II is the primary cytotoxic target of some of the
most eVective chemotherapeutic drugs, such as the epipod-
ophylotoxins, etoposide (VP-16) and teniposide (VM-26)
[32]. Studies in previously untreated patients with advanced
colorectal carcinoma evaluating the combination of etopo-
side with cisplatin or 5-FU demonstrated minimal activity
in metastatic colorectal cancer [48–51]; there have been no
clinical data supporting the in vitro synergy observed
between these cytotoxic agents [52,  53]. Other studies
failed to prove any beneWt with the combination of etopo-
side with 5-FU or cisplatin/carboplatin [54]. However, the
combination of etoposide with 5-FU + LV had demon-
strated some activity when administered as second-line
treatment after failure of weekly 5-FU + LV in patients
with metastatic colorectal cancer [55, 56].
The results reported herein underscore the role of topoi-
somerase (topo-I and topo-II) expression in colorectal
cancer. It is believed that translational studies of molecular
targets for currently applied cytotoxic and biological agents
(like bevacizumab and cetuximab) might form the basis of
current and future drug combinations, in rationalizing the
optimal chemotherapeutic drug schedule and sequence that,
will eventually translate in improved tumor eradication and
survival prolongation.
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